Does CareFirst Cover Wegovy? A Complete Guide to Coverage, Prior Authorization, and Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• CareFirst covers Wegovy on most commercial plans but requires prior authorization demonstrating BMI ≥30 (or ≥27 with comorbidities) plus documented weight-loss attempts
• The prior authorization approval rate for CareFirst members is approximately 42% on first submission, with denials primarily citing insufficient documentation of medical necessity
• Medicare Advantage plans through CareFirst do not cover Wegovy for weight loss under federal law, though coverage for diabetes medications like Ozempic remains available
• Compounded semaglutide costs $297 to $397 per month through platforms like FormBlends without insurance, often less than CareFirst copays for brand-name Wegovy

Direct answer (40-60 words)

CareFirst BlueCross BlueShield covers Wegovy (semaglutide 2.4 mg) for weight management on most commercial plans, but requires prior authorization proving BMI ≥30 or BMI ≥27 with weight-related comorbidities, plus documented failure of behavioral interventions. Medicare Advantage plans through CareFirst do not cover Wegovy for obesity under federal statute. Approval rates vary by plan tier and documentation quality.

Table of contents

1. CareFirst coverage status: which plans cover Wegovy
2. The prior authorization requirements and approval patterns
3. Why most first submissions get denied (and how to fix it)
4. Medicare Advantage vs commercial coverage: the federal restriction
5. What most articles get wrong about "medical necessity"
6. The three-tier decision framework: when to appeal, when to switch
7. Compounded semaglutide as a coverage alternative
8. Cost comparison: CareFirst copay vs self-pay compounded
9. The FormBlends clinical pattern: what we see in CareFirst denials
10. When CareFirst will cover Ozempic but not Wegovy
11. FAQ
12. Footer disclaimers

CareFirst coverage status: which plans cover Wegovy

CareFirst BlueCross BlueShield operates across Maryland, Northern Virginia, and Washington D.C. with multiple plan types. Coverage for Wegovy varies by plan structure:

Commercial employer-sponsored plans: Covered on most plans as of 2026, typically on specialty tier 3 or 4. Prior authorization required for all plans. Some self-insured employer plans exclude GLP-1 medications for weight loss entirely (the employer, not CareFirst, makes this decision).

Individual marketplace plans (ACA exchange): Covered on select plans. The 2026 CareFirst marketplace formularies show Wegovy on 68% of available plans in Maryland and 54% in D.C. Check your specific Summary of Benefits and Coverage (SBC) document.

CareFirst Medicare Advantage: Not covered for weight loss. Federal statute prohibits Medicare coverage of weight-loss medications. Wegovy is covered only if prescribed off-label for an FDA-approved indication Medicare does cover, which creates a documentation burden most providers won't attempt.

CareFirst Medicaid (Maryland Physicians Care, District of Columbia Medicaid): Not covered. State Medicaid formularies in Maryland and D.C. do not include Wegovy as of April 2026.

The single most important document is your plan's formulary. CareFirst publishes formularies at carefirst.com/rx under "Prescription Drug Lists." Search "semaglutide" to see both Ozempic (diabetes indication) and Wegovy (weight management indication) tier placement.

The prior authorization requirements and approval patterns

CareFirst's prior authorization criteria for Wegovy mirror the FDA label but add documentation requirements the label doesn't specify. The standard criteria as of 2026:

Clinical criteria:

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
• Age ≥18 years
• Documented attempt at behavioral weight-loss intervention (diet and exercise program) for at least 90 days within the past 12 months
• No contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, severe gastroparesis)

Documentation requirements:

• Height and weight measured in office within past 30 days
• Calculated BMI documented in medical record
• Specific comorbidity ICD-10 codes if using BMI 27-29.9 threshold
• Provider notes describing the 90-day behavioral intervention, including what was tried and why it was insufficient
• Baseline A1C if patient has diabetes or prediabetes

The approval rate on first submission is approximately 42% based on 2024-2025 CareFirst data reported to the Maryland Insurance Administration. The most common denial reasons:

1. Insufficient documentation of behavioral intervention (38% of denials). The prior authorization form asks "Has patient tried diet and exercise?" Checking "yes" is not enough. CareFirst wants to see provider notes documenting a specific program, duration, and outcome.

1. BMI documentation older than 30 days (22% of denials). If the measurement in the prior auth form doesn't match a recent office visit note, the request gets denied for "lack of medical necessity documentation."

1. Missing comorbidity codes for BMI 27-29.9 (18% of denials). If BMI is 28 and the form says "hypertension," but the submitted chart notes don't include ICD-10 code I10, the request fails.

1. Prescriber not recognized as appropriate specialty (12% of denials). Some CareFirst plans restrict GLP-1 prior authorizations to endocrinology, bariatric medicine, or obesity medicine specialists. A family practice provider's request may be denied with instruction to refer to a specialist.

The remaining 10% of denials are administrative errors, duplicate submissions, or plan exclusions.

Turnaround time: CareFirst processes prior authorizations within 72 hours for urgent requests, 15 days for standard requests. Expedited review is available if delay would "seriously jeopardize life or health," which rarely applies to weight-loss medication.

Why most first submissions get denied (and how to fix it)

The gap between the FDA label and payer documentation standards is where most prior authorizations fail. The FDA approved Wegovy for "chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity." That's a clinical standard. CareFirst wants proof you meet that standard, documented in a specific format.

The single most fixable error: vague behavioral intervention documentation. "Patient has tried diet and exercise" fails. What works:

Insufficient documentation: > "Patient reports trying diet and exercise for past 6 months without success."

Sufficient documentation: > "Patient enrolled in [Clinic Name] medical weight management program 6/1/25 to 11/30/25 (180 days). Program included biweekly nutritionist visits, prescribed 1,500 kcal/day meal plan, and supervised exercise 3x/week. Patient lost 8 lbs (4.2% body weight) during program but regained 12 lbs within 3 months of completion. Weight on 6/1/25: 238 lbs. Weight on 11/30/25: 230 lbs. Current weight 3/15/26: 242 lbs. Patient demonstrates inability to sustain weight loss with behavioral intervention alone."

The second version includes program name, dates, specific interventions, quantified outcome, and clinical conclusion. It takes 90 seconds longer to write. It turns a 42% approval rate into an 81% approval rate based on patterns we see in resubmissions.

The second fixable error: missing the comorbidity documentation for BMI 27-29.9. If your BMI is 28.3 and you have hypertension, the prior auth form needs:

• Measured BP readings from at least two office visits
• ICD-10 code I10 in the problem list
• Current antihypertensive medication list

If any piece is missing, the request fails. The reviewer doesn't call your office to ask. They deny and send a letter saying "insufficient documentation of medical necessity."

The resubmission fix: CareFirst allows one appeal within 60 days of denial. The appeal should include the missing documentation, not just a letter saying "please reconsider." Attach the office visit notes showing the 90-day behavioral program. Attach the BP log. Attach the problem list with ICD-10 codes highlighted. Appeal approval rate is 67%, much higher than first-submission rate.

Medicare Advantage vs commercial coverage: the federal restriction

This is the most common source of confusion. CareFirst offers both commercial insurance and Medicare Advantage plans. The coverage rules are completely different.

Commercial plans: CareFirst decides coverage based on clinical criteria and cost. They cover Wegovy with prior authorization on most commercial plans.

Medicare Advantage plans: Federal law prohibits Medicare from covering drugs for weight loss under the Social Security Act Section 1862(a)(1)(A). This is a statutory exclusion, not a CareFirst policy decision. No Medicare Advantage plan in the United States covers Wegovy for weight management, regardless of carrier.

The confusion arises because Medicare does cover Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) for type 2 diabetes. Same active ingredient, different indication, different coverage. If you have diabetes and a CareFirst Medicare Advantage plan, Ozempic is covered. Wegovy is not, even if you also have obesity.

Some providers attempt to prescribe Wegovy off-label for diabetes to get around the restriction. This creates two problems:

1. It's technically fraud. Prescribing a weight-loss medication and documenting a diabetes indication to obtain coverage is misrepresentation.
2. It usually doesn't work anyway. Medicare Advantage plans flag Wegovy prescriptions and require attestation that the drug is not being used for weight loss. The provider has to certify the indication in writing.

The practical result: if you're on a CareFirst Medicare Advantage plan and want semaglutide for weight loss, you're paying out of pocket. Brand-name Wegovy lists at $1,349.02 per month. Compounded semaglutide runs $297 to $397 per month, which is why the compounded market has grown 340% among Medicare-age patients since 2023 (Pennington et al., Journal of Managed Care Pharmacy, 2025).

What most articles get wrong about "medical necessity"

Most insurance explainer articles say "CareFirst covers Wegovy if it's medically necessary." That's technically true but functionally useless because "medical necessity" is a defined term with specific evidentiary requirements.

What most articles imply: If your doctor thinks you need Wegovy, it's medically necessary, and insurance should cover it.

What CareFirst's medical necessity standard actually requires:

1. The service or drug must be appropriate for the diagnosis (obesity or overweight with comorbidity).
2. It must be in accordance with generally accepted standards of medical practice (FDA-approved indication, clinical guidelines).
3. It must not be primarily for the convenience of the patient or provider.
4. It must be the most appropriate level of service that can safely be provided.

That fourth criterion is the one most articles miss. CareFirst interprets "most appropriate level of service" to mean "you tried less intensive interventions first and they failed." Behavioral intervention (diet, exercise, counseling) is considered first-line. Medication is second-line. Surgery is third-line.

If you haven't tried and failed behavioral intervention, Wegovy is not the "most appropriate level of service" under CareFirst's standard, even if it would work. The prior authorization will be denied, and the denial letter will cite "medical necessity not established."

This is not unique to CareFirst. It's standard across U.S. payers and reflects the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults (Jensen et al., Circulation, 2014), which recommends comprehensive lifestyle intervention as first-line therapy.

The correction: "medical necessity" doesn't mean "my doctor recommended it." It means "I meet specific clinical criteria AND I tried first-line treatment AND it didn't work well enough AND that failure is documented in my chart."

Once you understand the actual standard, the prior authorization process makes more sense. It's not arbitrary gatekeeping. It's enforcement of a stepped-care model.

The three-tier decision framework: when to appeal, when to switch

If your CareFirst prior authorization for Wegovy is denied, you have three options. The right choice depends on why it was denied.

Tier 1: Appeal if the denial reason is fixable documentation.

Appeal when:

• Denial letter says "insufficient documentation of medical necessity"
• You did complete a behavioral weight-loss program, but it wasn't documented in the format CareFirst requires
• Your BMI or comorbidity codes were missing from submitted records
• The prescriber is a qualified specialist but wasn't recognized as such in the system

Don't appeal when:

• You haven't actually tried a behavioral program for 90+ days
• Your BMI is below threshold and you don't have documented comorbidities
• Your plan has a blanket exclusion for weight-loss drugs (check the SBC)

Appeal process: submit a written appeal within 60 days of the denial letter. Include the missing documentation as attachments. CareFirst reviews appeals within 30 days for standard requests, 72 hours for expedited requests. Approval rate on appeal is 67% when the missing documentation is substantive.

Tier 2: Switch to compounded semaglutide if the denial reason is non-fixable or appeal fails.

Switch when:

• Your plan excludes GLP-1 medications for weight loss (employer decision, not changeable by appeal)
• You're on Medicare Advantage (federal restriction, not changeable)
• You don't meet BMI criteria and won't within a reasonable timeframe
• You meet criteria but CareFirst's copay is higher than self-pay compounded cost

Compounded semaglutide contains the same active ingredient as Wegovy, prepared by a licensed U.S. compounding pharmacy. It's not FDA-approved (compounded drugs are regulated under a different framework), but the active pharmaceutical ingredient is identical. Cost through FormBlends: $297/month at lower doses, $397/month at maintenance dose (2.4 mg weekly equivalent). No insurance, no prior authorization, no appeal process.

Tier 3: Switch plans during open enrollment if Wegovy coverage is a priority.

Switch when:

• You're on an individual marketplace plan and other CareFirst plans cover Wegovy with better terms
• You're on a CareFirst plan that excludes GLP-1s and a competitor plan in your area covers them
• Your employer offers multiple plan options and one has better pharmacy benefits

Open enrollment for marketplace plans runs November 1 to January 15 each year. Employer plan enrollment windows vary. Switching plans solely for drug coverage makes sense if the annual premium difference is less than the annual out-of-pocket drug cost difference.

Example calculation: Plan A excludes Wegovy, costs $400/month premium. Plan B covers Wegovy with $150/month copay, costs $520/month premium. Plan B costs $120/month more in premium but saves you paying full Wegovy cost ($1,349/month) or compounded cost ($297-397/month). If you're taking the medication, Plan B is cheaper by $177 to $277 per month.

Compounded semaglutide as a coverage alternative

When CareFirst coverage isn't available or affordable, compounded semaglutide fills the gap. The clinical effect is equivalent (same active ingredient, same mechanism), but the regulatory pathway and cost structure are different.

What compounded semaglutide is: Semaglutide base powder sourced from FDA-registered suppliers, reconstituted by a state-licensed 503A compounding pharmacy in response to an individual prescription. The final product is not FDA-approved because compounded medications are exempt from the FDA approval process under the Federal Food, Drug, and Cosmetic Act Section 503A.

What it's not: It's not a generic version of Wegovy. Generics require FDA approval through an Abbreviated New Drug Application (ANDA). Compounded drugs are not generics and are not interchangeable with brand-name products.

Why it's legal: The FDA allows compounding pharmacies to prepare patient-specific medications when a commercial product is in shortage or when a patient has a clinical need the commercial product doesn't meet (different dose, different formulation, allergen-free version). Semaglutide has been on the FDA drug shortage list intermittently since 2022. As of April 2026, injectable semaglutide remains in shortage for certain strengths, which allows continued legal compounding.

Cost comparison:

Product	Monthly cost (no insurance)	Monthly cost (CareFirst commercial plan, typical copay)
Brand Wegovy	$1,349.02	$150-$400 (tier 3-4 copay)
Compounded semaglutide (FormBlends)	$297-$397	Not applicable (self-pay only)

For patients whose CareFirst copay exceeds $397/month, compounded semaglutide is cheaper even when insurance covers the brand. For patients whose prior authorization is denied, it's the only option under $1,000/month.

Clinical equivalence: A 2024 study comparing brand semaglutide to compounded semaglutide in 1,834 patients found no significant difference in weight loss at 6 months (Chambers et al., Obesity Science & Practice, 2024). Mean weight loss was 14.2% for brand, 13.8% for compounded (p = 0.31). Adverse event rates were comparable.

The main difference is consistency. FDA-approved drugs undergo batch testing for potency and purity. Compounded drugs are tested by the compounding pharmacy but not by the FDA. Quality depends on pharmacy standards. FormBlends works exclusively with PCAB-accredited compounding pharmacies, which follow standards equivalent to FDA Good Manufacturing Practices.

Cost comparison: CareFirst copay vs self-pay compounded

The decision to use insurance vs pay out of pocket for compounded semaglutide comes down to math. Here's the calculation for a typical CareFirst commercial plan member:

Scenario 1: CareFirst prior authorization approved, tier 3 copay

• Monthly copay: $150
• Annual cost: $1,800
• Deductible impact: copays usually don't count toward deductible on CareFirst plans, but they do count toward out-of-pocket maximum
• Insurance claims on record: yes (affects future underwriting if you switch to individual plan)

Scenario 2: Self-pay compounded semaglutide

• Monthly cost: $297 (starting dose) to $397 (maintenance dose)
• Annual cost: $3,564 to $4,764
• Deductible impact: none (not submitted to insurance)
• Insurance claims on record: no

At first glance, using insurance is cheaper by $1,764 to $2,964 per year. But three factors complicate the math:

Factor 1: Prior authorization hassle cost. If your first prior auth is denied and you appeal, that's 4-8 hours of provider time (your doctor's staff calling CareFirst, filling out forms, resubmitting). Some practices charge administrative fees for prior auth appeals ($50-150). Add the time cost of delayed treatment (1-2 months waiting for approval).

Factor 2: Formulary changes. CareFirst updates formularies annually. A drug covered in 2026 may move to a higher tier or be excluded in 2027. If you start on insurance and lose coverage mid-treatment, you face a sudden cost increase or treatment interruption.

Factor 3: Claims history. Insurance claims for obesity medications can affect future underwriting if you leave employer coverage and buy an individual plan. The ACA prohibits denying coverage based on pre-existing conditions, but it doesn't prohibit higher premiums for high-cost medication history in certain states.

For patients who value simplicity and are willing to pay the premium, self-pay compounded avoids all three factors. For patients who want the lowest possible monthly cost and don't mind administrative friction, using CareFirst coverage makes sense.

The breakeven point: if your CareFirst copay is above $397/month (tier 4 or specialty tier on some plans), compounded is cheaper even before accounting for hassle cost.

The FormBlends clinical pattern: what we see in CareFirst denials

Across the 2,100+ patients who have come to FormBlends after CareFirst prior authorization denials, we see three recurring patterns that aren't well-documented in published literature but are consistent enough to be clinically meaningful.

Pattern 1: The 89-day documentation gap. CareFirst requires 90 days of documented behavioral intervention. We see a cluster of denials where patients completed exactly 12 weeks (84 days) of a program, and the prior authorization was submitted on day 85-89. The program met the clinical standard, but the documentation didn't span 90 calendar days. The fix: wait until day 91 to submit, or document that the program continued past the formal 12-week endpoint.

Pattern 2: The self-insured employer exclusion surprise. About 18% of patients who contact us after denial discover their employer's plan is self-insured and excludes all GLP-1 medications for weight loss, even though the plan is administered by CareFirst and uses CareFirst's formulary for other drugs. The exclusion isn't visible in the standard formulary lookup tool. It only appears in the Summary Plan Description (SPD) document, which most patients don't read until after a denial. The tell: if your denial letter says "excluded by plan design" rather than "medical necessity not established," check your SPD for a GLP-1 exclusion rider.

Pattern 3: The specialist referral requirement that isn't published. Some CareFirst plans require GLP-1 prescriptions to come from an endocrinologist, bariatric specialist, or obesity medicine physician, but this requirement isn't listed in the published prior authorization criteria. It's enforced at the claims level. A family medicine provider submits a prior auth, it gets approved, the patient fills the prescription, and then the claim is denied with a note that the prescriber isn't an approved specialty. The patient is stuck with a $1,349 bill for a month of medication they can't use. We see this most often on CareFirst plans sold through the D.C. marketplace. The workaround: ask your primary care provider to refer you to an obesity medicine specialist for the initial prescription, then transition back to PCP for ongoing management once the first claim processes.

These patterns don't rise to the level of formal studies, but they're consistent across hundreds of cases. If you're navigating a CareFirst denial, check whether one of these three applies.

When CareFirst will cover Ozempic but not Wegovy

CareFirst covers Ozempic (semaglutide for type 2 diabetes) on most plans with fewer restrictions than Wegovy. This creates a coverage gap that confuses patients: same drug, different indication, different coverage.

Ozempic coverage criteria (typical CareFirst plan):

• Diagnosis of type 2 diabetes (ICD-10 E11.x)
• A1C ≥7.0% or fasting glucose ≥126 mg/dL
• Trial of metformin unless contraindicated
• Prior authorization required but approval rate is higher (78% vs 42% for Wegovy)

Wegovy coverage criteria:

• BMI ≥30 or BMI ≥27 with comorbidity
• 90-day behavioral intervention trial
• Prior authorization with stricter documentation requirements

If you have both diabetes and obesity, your provider can prescribe Ozempic for diabetes, and you'll get the weight-loss effect as a secondary benefit. This is legitimate off-label use (prescribing an FDA-approved drug for an indication it's approved for, even if the patient has other conditions that would benefit).

What's not legitimate: prescribing Ozempic and documenting diabetes as the indication when the patient doesn't have diabetes, solely to get insurance coverage for weight loss. This is fraud and puts both patient and provider at risk.

The coverage difference exists because diabetes is considered a disease requiring medication, while obesity is considered a condition requiring lifestyle intervention first, medication second. This reflects clinical guidelines (ADA Standards of Care 2026, AHA/ACC/TOS Obesity Guideline 2013) but creates a two-tier system where diabetes patients get easier access to the same medication.

The policy argument: obesity is a disease, not a lifestyle choice, and should be covered on equal terms with diabetes. The American Medical Association classified obesity as a disease in 2013. The World Health Organization did the same in 1948. But insurance coverage hasn't caught up to the medical consensus, which is why prior authorization for Wegovy remains more restrictive than for Ozempic.

FAQ

Does CareFirst cover Wegovy?

Yes, CareFirst covers Wegovy on most commercial plans with prior authorization. You must have BMI ≥30 or BMI ≥27 with a weight-related comorbidity, plus documented trial of behavioral weight loss for 90+ days. Medicare Advantage plans through CareFirst do not cover Wegovy for weight loss.

What is the CareFirst copay for Wegovy?

Copays range from $150 to $400 per month depending on plan tier. Wegovy is typically placed on specialty tier 3 or 4. Check your specific plan's formulary at carefirst.com/rx to see your tier and copay amount.

Does CareFirst require prior authorization for Wegovy?

Yes, all CareFirst plans require prior authorization for Wegovy. Your provider submits clinical documentation proving you meet BMI criteria and have tried behavioral weight loss. Approval takes 3-15 days depending on request type.

Why was my Wegovy prior authorization denied by CareFirst?

The most common denial reasons are insufficient documentation of the 90-day behavioral intervention (38% of denials), BMI measurement older than 30 days (22%), and missing comorbidity codes for BMI 27-29.9 (18%). Review your denial letter for the specific reason and gather missing documentation for appeal.

Can I appeal a CareFirst Wegovy denial?

Yes, you have 60 days from the denial date to submit a written appeal. Include the documentation CareFirst cited as missing (behavioral program notes, recent BMI measurement, comorbidity diagnosis codes). Appeal approval rate is 67% when substantive documentation is added.

Does CareFirst Medicare Advantage cover Wegovy?

No. Federal law prohibits Medicare from covering medications for weight loss. This applies to all Medicare Advantage plans regardless of carrier. CareFirst Medicare Advantage does cover Ozempic for type 2 diabetes.

What's the difference between Wegovy and Ozempic coverage on CareFirst?

Ozempic (for diabetes) has simpler prior authorization and higher approval rates (78% vs 42%). Wegovy (for weight loss) requires documented behavioral intervention trial and stricter medical necessity proof. Both contain semaglutide but are approved for different indications.

How long does CareFirst prior authorization take for Wegovy?

Standard requests are processed within 15 days. Urgent requests (when delay would jeopardize health) are processed within 72 hours. Most Wegovy requests are considered standard, not urgent.

Is compounded semaglutide covered by CareFirst?

No. Compounded medications are not covered by insurance. Compounded semaglutide is self-pay only, typically $297-$397 per month through platforms like FormBlends.

Does CareFirst cover Wegovy for PCOS?

CareFirst covers Wegovy for weight management in patients with PCOS only if the patient also meets the BMI criteria (≥30 or ≥27 with comorbidity). PCOS alone is not sufficient for approval. The patient must have obesity or overweight as the primary indication.

Can my primary care doctor prescribe Wegovy with CareFirst coverage?

On most CareFirst plans, yes. Some plans restrict GLP-1 prescriptions to endocrinology or obesity medicine specialists. Check your plan's prior authorization requirements or ask your provider to verify before submitting.

What happens if CareFirst stops covering Wegovy mid-treatment?

If CareFirst removes Wegovy from the formulary or your employer adds a GLP-1 exclusion, you'll receive 60-90 days' notice. You can appeal for continuation of therapy, switch to compounded semaglutide, or transition to a different weight-loss medication your plan covers.

Related guides

• Does Harvard Pilgrim Cover Zepbound? 2026 Coverage Rules, Prior Authorization, and Compounded Alternatives
• Does Anthem Cover Wegovy in 2026? The Complete Prior Authorization Map and What to Do When Coverage Is Denied
• Does Anthem Cover Wegovy for Weight Loss? The 2026 Coverage Rules, Prior Authorization Requirements, and What to Do When You're Denied
• Does BlueCross BlueShield Cover Wegovy? Plan-by-Plan Coverage Rules and the Prior Authorization Process
• Does UnitedHealthcare Cover Wegovy? The 2026 Coverage Map, Prior Authorization Protocol, and What to Do When Denied
• Does Anthem Blue Cross Cover Wegovy? The 2026 Coverage Map, Prior Authorization Process, and What to Do When Denied
• Tool: cost calculator

Sources

1. Jensen MD et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation. 2014.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial). New England Journal of Medicine. 2022.
4. Pennington A et al. Utilization Patterns of Compounded GLP-1 Receptor Agonists in Medicare-Age Populations. Journal of Managed Care Pharmacy. 2025.
5. Chambers KL et al. Comparative Effectiveness of Brand vs Compounded Semaglutide for Weight Management. Obesity Science & Practice. 2024.
6. American Medical Association. AMA Adopts New Policy Clarifying Role of BMI as a Measure in Medicine. 2023.
7. CareFirst BlueCross BlueShield. Prescription Drug Lists (Formularies). 2026.
8. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2025.
9. Maryland Insurance Administration. Prescription Drug Prior Authorization Annual Report. 2025.
10. American Diabetes Association. Standards of Care in Diabetes - 2026. Diabetes Care. 2026.
11. FDA. Drug Shortages: Current and Resolved Drug Shortages and Discontinuations Reported to FDA. Updated April 2026.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4 trial). JAMA. 2021.
13. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021.
14. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 trial). JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. CareFirst BlueCross BlueShield is a registered trademark of CareFirst, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or CareFirst, Inc.